Answers are grounded in this paper and cite their sources.
The effect of preformed donor‐specific antibodies (DSAs) on liver transplantation (LT) remains unclear, especially in the field of living donorLT(LDLT). Herein, we evaluated the prevalence of preformedDSAs and their effect on graft outcome inLDLTin the first year following surgery. Using the Luminex®Single Antigen assay, we analyzed the preoperative sera of 61 adultLDLTrecipients between 2014 and 2015. Clinical outcomes and pathologic findings including complement component 4d (C4d) expression in the first year afterLTwere retrospectively reviewed. Regardless of the class ofDSA,DSAs with mean fluorescence intensity (MFI) ≥1000 were defined as positive and preformedDSAwithMFI≥5000 was defined as strongly positive. Fifteen patients (24.6%) had preformedDSAs, and 8 patients (13.1%) showed strongly positive preformedDSAs. Among 15DSApositive patients, 2 (13.3%) showed persistentDSAs afterLDLT. No de novoDSAs were noted in patients without preformedDSAs. PreformedDSAs were not related to graft dysfunction, laboratory values, or C4d expression or other pathologic findings in the first year ofLDLT. In conclusion, preformedDSAs persisted during follow‐up in 13.3% of cases and did not have adverse effect on histologic or clinical outcomes in the first year ofLDLT.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: